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Abstract
Background: To examine the extent to which state adoption of the Centers for Disease Control and Prevention
(CDC) 2006 revisions to adult and adolescent HIV testing guidelines is associated with availability of other important
prevention and medical services. We hypothesized that in states where the pretest counseling requirement for HIV
testing was dropped from state legislation, substance use disorder treatment programs would have higher
availability of HCV testing services than in states that had maintained this requirement.
Methods: We analyzed a nationally representative sample of 383 opioid treatment programs from the 2005 and
2011 National Drug Abuse Treatment System Survey (NDATSS). Data were collected from program directors and
clinical supervisors through telephone surveys. Multivariate logistic regression models were used to measure
associations between state adoption of CDC recommended guidelines for HIV pretest counseling and availability of
HCV testing services.
Results: The effects of HIV testing legislative changes on HCV testing practices varied by type of opioid treatment
program. In states that had removed the requirement for HIV pretest counseling, buprenorphine-only programs
were more likely to offer HCV testing to their patients. The positive spillover effect of HIV pretest counseling policies,
however, did not extend to methadone programs and did not translate into increased availability of on-site HCV
testing in either program type.
Conclusions: Our findings highlight potential positive spillover effects of HIV testing policies on HCV testing practices.
They also suggest that maximizing the benefits of HIV policies may require other initiatives, including resources and
programmatic efforts that support systematic integration with other services and effective implementation.
Keywords: HIV testing policies, HIV testing guidelines, HIV pretest counseling, HCV testing, Drug treatment, Programs,
Methadone, Buprenorphine, Centers for disease control and prevention
Background
To increase HIV testing, promote earlier detection of HIV
infection, counsel and link infected persons to HIV clinical
and prevention services, the Centers for Disease Control
and Prevention (CDC) published revised recommenda-
tions for HIV testing in health care settings for adults and
adolescents in 2006 [1]. These recommendations stated
that general consent for medical care is sufficient for HIV
testing, thus eliminating the need for a separate written
consent prior to HIV testing. The CDC also recommended
eliminating mandatory pretest counseling about risk be-
haviors and risk reduction. Several studies have indeed
found that pretest counseling was time-consuming and
placed a high burden on staff members, while having lim-
ited impact on subsequent risk of infection with HIV or
other sexually transmitted infections (STIs) [2–4]. A recent
randomized controlled trial conducted in drug treatment
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centers found that there were no significant differences in
the acquisition STIs and transmission of HIV between
groups that received pretest counseling and those that did
not [5, 6].
While CDC recommendations may influence state laws,
the authority to set or modify HIV testing policies is under
the jurisdiction of states. States must decide to amend laws
to conform or at a minimum to not conflict with CDC
recommendations [7]. By 2011, forty-six states and juris-
dictions (including Washington D.C.) had adopted legisla-
tion that was compatible with the 2006 CDC guidelines
for consent and counseling [8]. These legislative changes
appear to have improved the availability and range of HIV
services offered at health facilities, as well as the number
of patients learning their HIV status [5, 6, 9–13].
The effects of HIV-related legislative changes on the
availability of other medical services, on the other hand,
have seldom been investigated, even though such effects
may be present. The elimination of HIV pretest counsel-
ing, for example, may considerably reduce the need for
human and financial resources dedicated to HIV testing.
These resources could then be redirected towards offering
new preventive services or to improving the quality of
existing services [4, 14]. Similarly, investments in equip-
ment or human resources required to respond to the in-
creased volume of HIV testing may also present a prime
opportunity for providing additional prevention, testing or
treatment services more widely and efficiently. Lastly, in-
creased emphasis on HIV testing may influence attitudinal
changes among clinical and managerial staff. This may
lead to increased support for preventive services more
generally.
Services addressing infection with the Hepatitis-C Virus
(HCV) may be particularly affected by changes in HIV-
related legislation. This is so because both viruses partially
share routes of transmission and co-infection is common
[15, 16]. HIV and HCV co-infection is common in the U.S.,
with nearly 25 % of HIV-infected individuals also infected
with HCV [17, 18]. HIV and HCV testing also share similar
testing modalities. As for HIV testing protocols based on
enzyme immunoassays (EIA), common testing protocols for
HCV require phlebotomy and follow a two-step process:
first, blood samples are tested for the presence of HCV anti-
bodies, then reactive results are confirmed through ribo-
nucleic acid (RNA) testing. A rapid test for HCV antibodies
also exists but has been approved by the US Food and Drug
Administration (FDA) significantly later than rapid HIV
tests. Unlike HIV testing, the CDC has not published spe-
cific consent or pretest counseling guidelines for HCV test-
ing. Legislative changes designed to increase the availability
and uptake of HIV-related services may thus potentially
lead to changes in the availability of HCV-related services.
Such “spillover effects” are important because they
may optimize the efficiency and effectiveness of service
delivery, through integration of care, and the availability
of comprehensive services. These models of care have
the potential to increase access, quality, and health out-
comes [19, 20]. Spillover effects also have implications
that may affect assessments of the cost-effectiveness of
HIV-related policies [21].
In this paper, we examined whether the adoption of state
legislation compatible with the 2006 CDC guidelines on
HIV testing was associated with subsequent improvements
in the availability of HCV testing services. We focus on
the elimination of the requirement for HIV pretest coun-
seling in opioid treatment programs (OTPs). OTPs are
physical facilities with resources dedicated specifically to
treating opiate dependence through methadone or bupre-
norphine (excluding primary care or physician offices).
OTPs treat approximately 26% of all individuals enrolled
in substance use disorder (SUD) treatment programs the
Unites States [22]. The prevalence of HIV and HCV is high
among patients of OTPs, particularly persons who inject
drugs [23–25]. In addition, whereas persons who use or in-
ject drugs are less likely to regularly seek services in pri-
mary healthcare settings [26, 27], they frequently attend
SUD treatment facilities. OTPs thus constitute an import-
ant setting for increasing the diagnosis of HIV, HCV and
other infectious diseases among persons with SUD.
We hypothesized that in states where the pretest counsel-
ing requirement for HIV testing was dropped from state le-
gislation, OTPs would have higher availability of HCV
testing services than in states that had maintained this re-
quirement. Indeed, simplifying HIV testing protocols may
help OTPs invest time and resources in the provision of
HCV testing services to their clients. An increasing number
of OTPs are buprenorphine-only programs: they repre-
sented 14 % of all OTPs in 2005 vs. 27 % in 2011 [28].
Buprenorphine-only programs are often smaller programs,
with fewer human resources and connections to hospitals
or laboratories. They are also the least likely type of OTPs
to provide HIV testing [9] and/or HCV testing [29] to their
patients. Programs that offer methadone, on the other
hand, more frequently offer a broad range of medical
and preventive services to their patients. The associ-
ation between changes in HIV testing policies and
the supply of HCV testing services may thus vary be-
tween buprenorphine-only and methadone OTPs.
Methods
Data sources
We analyzed data from the National Drug Abuse Treatment
System Survey (NDATSS). The NDATSS is a nationally-
representative survey, which examines the organizational
structures and operating characteristics of the nation’s out-
patient SUD treatment programs [30]. Because the Sub-
stance Abuse and Mental Health Services Administration
(SAMHSA) certifies OTPs, we obtained lists that precisely
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identify the entire US population of approved OTPs as the
sampling frame. The sample is nationally representative, al-
though each wave may not include treatment OTPs from
all states due to sampling variation. In addition, the
SAMHSA list only includes OTPs, i.e., facilities that are
dedicated to the treatment of opioid dependence. Our sam-
pling frame thus does not include primary healthcare facil-
ities that dispense buprenorphine. Primary health care
facilities are not registered by SAMHSA. Rather, the re-
quirement is that health care providers undergo a short
training course and obtain a US Drug Enforcement Admin-
istration (DEA) registration number in order to prescribe
buprenorphine. OTPs that prescribe buprenorphine (be-
cause they have a provider with a DEA registration number)
are included in our sample. The Columbia University Insti-
tutional Review Board reviewed and approved the study. In-
formed consent to participate in the study was obtained
orally prior to administering the surveys. During each wave
of the NDATSS, the administrative director and clinical
supervisor at each of the participating programs were asked
to complete a telephone survey on treatment practices and
program characteristics. Only aggregate anonymous data on
patient care and services were collected from programs.
The NDATSS team never reviewed individual patient re-
cords. The reliability and validity of the NDATSS, as well as
detailed description of the sampling frame and sample,
are available from other sources [9, 29, 31]. We used
data from all OTPs surveyed in the 2005 (n = 187) and
2011 (n = 196) NDATSS.
Dependent variables
HCV testing practices in OTPs were ascertained from
NDATSS questions that asked whether OTPs offered any
option for HCV testing to their patients, and if so,
whether such services were provided on-site or off-site.
We constructed two dependent variables from answers to
these questions. First, we created a binary variable (0–1)
set to 1 if the program offered any HCV testing option to
their patients (either on-site or off-site) and 0 otherwise.
Given the greater coordination and investment that may
be required to offer on-site HCV testing compared to off-
site testing, a second binary variable examined the avail-
ability of on-site HCV testing services, among OTPs that
offered any HCV testing option to their patients. OTPs
providing on-site HCV testing were coded 1, and those
providing only off-site services were coded 0.
Classification of states’ legislations
A variable describing state-level HIV-related legislation
was constructed based on three previous studies of
states’ HIV testing laws. Wolf et al. [32] and Mahajan et
al. [7] examined state HIV laws in 2004 and 2008, re-
spectively, whereas Neff and Goldschmidt [8] examined
state law compliance with CDC recommendations in
2011. With these data, we generated a dichotomous vari-
able to reflect the compatibility of state-level legislation
with CDC guidelines for the elimination of HIV pretest
counseling. States were coded 1 if their legislation allowed
eliminating the requirement for pretest counseling (adopted
CDC guidelines), and 0 (did not adopt CDC guidelines).
The resulting classification of states in 2005 and 2011 ap-
pears in Table 1. In 2005, some states had already adopted
legislation that did not require pretest counseling.
Control variables
OTPs that treat a large proportion of patients with charac-
teristics indicating high-risk for HIV or HCV may have
greater likelihood of offering preventive services. Patient
factors accounted for in the models therefore included
prevalence of injection drug users (IDU) among patients
in each program and total number of OTP patients in the
past year and race/ethnicity [33]. Organizational charac-
teristics and resources may also influence treatment prac-
tices [29, 34, 35]. We adjusted for several characteristics of
OTPs including: sources of revenue (federal government,
private insurance), staff to patient ratio, Commission on
Accreditation of Rehabilitation Facilities (CARF) accredit-
ation, ownership (private for profit, private not for profit,
public) and hospital affiliation. We controlled for program
type (methadone-only, buprenorphine-only, both metha-
done and buprenorphine), which has been associated with
availability of HIV and HCV testing services [9, 29]. Finally,
we also controlled for time trends in the adoption of HCV
testing in OTPs by including a binary variable identifying
observations from the 2011 survey (1 = 2011, 0 = 2005).
Data analysis
We first reviewed state policies about HIV pretest coun-
seling in 2005 and 2011 and assessed their compatibility
with the 2006 CDC guidelines. We then described differ-
ences in OTP characteristics between programs offering
any HCV testing services (either on-site or off-site) to
their patients vs. OTPs in which no HCV testing services
were offered. We used the Pearson χ2 test for categorical
variables and the t test for continuous variables, and we
computed unadjusted odds ratios. Second, we estimated
multivariate logistic regression models to examine associa-
tions between state-level HIV-related legislation and avail-
ability of HCV testing services in OTPs, controlling for
program and patient characteristics [36]. Third, we used
multivariate logistic regressions to test whether, among
OTPs that did offer HCV testing services, state-level HIV-
related legislation was associated with increased adoption
of on-site HCV testing among OTPs that offered HCV
testing option to their patients. Finally, we tested whether
the association between state-level HIV-related legislation
and HCV testing services varied by type of drug treatment
(programs that offer buprenorphine only vs. programs that
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offer methadone, either methadone only or methadone
and buprenorphine) provided in OTPs. We did so by in-
cluding an interaction term in our logistic regression
models.
In all models, we addressed issues of unobserved het-
erogeneity (i.e., confounding variables that may affect
our estimates of the association between state legislation
and the availability of HCV testing at OTPs) by includ-
ing state fixed-effects [37]. This strategy permits control-
ling for all time-invariant characteristics of states that
may be associated with both the likelihood of adopting
legislation that enables changing the pretest counseling
requirement for HIV testing and the availability of HCV
testing in OTPs. We adjusted all standard errors for
clustering of observations within state. All analyses were
carried out using the STATA 12.0 (StataCorp LP, College
Station, TX).
Results
Only 4 states included in NDATSS had already adopted
HIV-related legislation that eliminated the requirement
for pretest counseling at the time of the 2005 NDATSS
wave. These included Georgia, Illinois, Maryland, and
New Mexico. On the other hand, most states had
adopted such legislation by 2011: only six states or juris-
dictions (Washington D.C., Oklahoma, Pennsylvania,
Rhode Island, Tennessee, and Wisconsin) in the 2011
NDATSS had retained legislation that did not permit
dropping the pretest counseling risk (Table 1).
Table 2 describes differences in the characteristics be-
tween OTPs in which HCV testing options were offered
to patients and OTPs where no HCV testing options
were offered. In bivariate analyses, offer of HCV testing
services in OTPs was associated with a lower proportion
of African-Americans among patients, a more favorable
staff-to-patient ratio, CARF accreditation and method of
treatment. OTPs, which offered both methadone and
buprenorphine to their patients, were more likely to also
offer HCV testing services than other OTPs. OTPs located
in states where HIV-related legislation enabled dropping
the pretest counseling requirement had higher availability
of HCV testing services (87.3 % vs. 75.3 %, p < 0.01). In
multivariate analyses with controls for organizational
characteristics and state-level fixed effects, however, there
Table 1 Adoption of CDC HIV pretest counseling guidelines in





N Eliminated HIV Pretest
Counseling
N
Alabama N 6 Y 4
Alaska N – Y 1
Arizona N 2 Y 7
Arkansas N 1 Y 1
California N 25 Y 16
Colorado N 5 Y 3
Connecticut N 2 Y 3
Delaware N 1 Y 1
DC N 3 Y –
Florida N 4 Y 5
Georgia Y 3 Y 5
Hawaii N – Y 1
Illinois Y 10 Y 14
Indiana N 2 Y 1
Iowa N 1 Y 1
Kansas N 2 Y 3
Kentucky N 2 Y 2
Louisiana N 2 Y 3
Maine N 5 Y 1
Maryland Y 8 Y 9
Massachusetts N 7 Y 3
Michigan N 4 Y 4
Minnesota N 1 Y 3
Missouri N 1 Y 4
Montana N 1 Y 1
New Jersey N 7 Y 6
New Mexico Y 2 Y 2
New York N 28 Y 38
North Carolina N 1 Y 3
Ohio N 9 Y 13
Oklahoma N 1 N –
Oregon N 5 Y 2
Pennsylvania N 18 N 13
Rhode Island N – N 1
South Carolina N 1 Y 1
Tennessee N 1 N –
Texas N 7 Y 9
Utah N 2 Y 2
Vermont N 1 Y 1
Virginia N 2 Y 4
Table 1 Adoption of CDC HIV pretest counseling guidelines in
states included in the National Drug Abuse Treatment System
Survey (NDATSS) (Continued)
Washington N 2 Y 4
West Virginia N 1 Y 1
Wisconsin N 1 N –
Note: The table shows elimination of HIV pretest counseling in states included
in the NDATSS. Y = State legislation eliminated pretest counseling; N = state
retained legislation that did not permit eliminating pretest counseling
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Table 2 Regression analyses of the association between adoption of CDC HIV pre-test counseling guidelines and availability of HCV






Ratio (95 % CI)b
Adjusted Odds
Ratio (95 % CI)b
State-level legislation enables eliminating HIV pretest counseling requirement <0.01
No 44 (24.7) 134 (75.3) 1 1
Yes 26 (12.7) 179 (87.3) 2.26 (1.32, 3.86) 0.87 (0.19, 4.07)
Prevalence of injection drug users 0.07
< 25 % 33 (24.8) 100 (75.2) 1 1
25-74 % 24 (14.9) 137 (85.1) 1.88 (1.05, 3.39) 2.21 (0.97, 5.04)
≥ 75 % 13 (15.5) 71 (84.5) 1.80 (0.89, 3.67) 1.44 (0.51, 4.11)
African-American patients 0.05
< 10 % 24 (13.9) 148 (86.1) 1 1
≥ 10 % 46 (21.8) 165 (78.2) 0.58 (0.34, 0.99) 0.85 (0.37, 1.94)
Hispanic patients 0.17
< 10 % 41 (20.9) 155 (79.1) 1 1
≥ 10 % 29 (15.5) 158 (84.5) 1.44 (0.85, 2.44) 1.27 (0.54, 2.97)
Revenue from federal government 0.85
None 50 (18.5) 220 (81.5) 1 1
≥ 1 % 20 (17.7) 93 (82.3) 1.06 (0.60, 1.87) 1.15 (0.53, 2.49)
Revenue from private insurance 0.18
None 35 (16.0) 184 (84.0) 1 1
≥ 1 % 35 (21.3) 129 (78.7) 0.70 (0.42, 1.18) 1.11 (0.51, 2.43)
Human resources
Log Staff-to-patient ratio, mean (SD) -3.56 (0.76) -3.31 (0.72) 0.01 1.53 (1.09, 2.16) 1.30 (0.82, 2.06)
CARF accreditation 0.01
No 45 (23.2) 149 (76.8) 1 1
Yes 25 (13.2) 164 (86.8 1.98 (1.16, 3.39) 2.23 (0.98, 5.08)
Ownership 0.78
Private not-for-profit 36 (19.6) 148 (80.4) 1 1
Private for profit 24 (16.6) 121 (83.4) 1.22 (0.69, 2.17) 0.91 (0.40, 2.08)
Public 10 (18.5) 44 (81.5) 1.07 (0.49, 2.33) 0.97 (0.33, 2.80)
Hospital affiliation 0.09
No 64 (19.7) 261 (80.3) 1 1
Yes 6 (10.3) 52 (89.7) 2.12 (0.87, 5.17) 3.39 (1.13, 10.2)
Methods of treatment <0.01
Methadone only 45 (20.7) 172 (79.3) 1 1
Buprenorphine only 22 (23.2) 73 (76.8) 0.87 (0.49, 1.55) 1.55 (0.62, 3.88)
Methadone + Buprenorphine 3 (4.2) 68 (95.8) 5.93 (1.78, 19.8) 6.63 (1.61, 27.4)
Time <0.01
2005 50 (26.7) 137 (73.3) 1 1
2011 20 (10.2) 176 (89.8) 3.21 (1.82, 5.65) 3.20 (0.87, 11.7)
N 70 (18.3) 313 (81.7) 383 292c
Notes: apercentages in parentheses are row percentages; badjusted odds ratios are obtained from a logistic regression in which all variables in the table are included as
independent variables. Standard errors are adjusted for clustering of observations by state. cOnly states in which laws changed between 2005 & 2011 are included in
model with state-level fixed effects. p-value derived from a Wald test showed that at least one of the state dummies included in the model is significant at p < 0.05
Frimpong et al. BMC Public Health  (2016) 16:666 Page 5 of 12
were no significant differences in HCV testing availability
between states whose legislation permitted dropping the
HIV pretest counseling requirement and other states
(aOR = 0.87, 95 % CI = 0.19, 4.07).
The association between state-level HIV-related legis-
lation and the availability of HCV testing services dif-
fered significantly by type of treatment program (Fig. 1,
Wald test of interaction p-value <0.05). In programs of-
fering methadone-only or methadone and buprenor-
phine to their patients, 80 % of OTPs located in states
that had dropped the requirement for HIV pretest coun-
seling offered HCV testing services vs. 87 % in states
that still required pretest counseling. In OTPs that of-
fered only buprenorphine, on the other hand, 88 % of
OTPs in states that had dropped the pretest counseling
requirement offered HCV testing services vs. only 68 %
in states that had maintained this requirement (p < 0.05).
In bivariate analyses, among OTPs that offered HCV
testing to their patients, the type of HCV testing services
offered (on-site vs. off-site referral) was associated with
the prevalence of IDUs among patients, funding from
the federal government, more favorable staff-to-patient
ratios, OTP ownership, hospital affiliation and method
of treatment (Table 3). OTPs located in states that had
dropped the HIV pretest counseling requirement were
less likely to offer on-site HCV testing than OTPs in
states that had maintained this requirement (40.8 % vs.
68.7 %, p < 0.01). However, in multivariate analyses, there
were no significant differences in the likelihood of offer-
ing on-site testing between these two types of states
(aOR = 1.65, 95 % CI = 0.32, 8.46).
Among OTPs that offered HCV testing services to
their patients, there was no interaction between HIV-
related legislation and the type of treatment program
(Fig. 2) in determining whether HCV testing was offered
on-site or off-site. Between 60-62 % of OTPs offering
methadone-only or methadone and buprenorphine to
their patients had on-site HCV testing vs. 28 % of OTPs
offering buprenorphine only to their patients.
Discussion
In this paper, we examined the potential spillover effects
of state-level HIV testing policies on the availability of
HCV testing in opioid treatment programs. We hypothe-
sized that in states where the pretest counseling require-
ment for HIV testing was dropped from state legislation,
OTPs would have higher availability of HCV testing ser-
vices than in states that had maintained this require-
ment. Indeed, simplifying the procedures for HIV testing
may help OTPs mobilize financial and/or human re-
sources for the provision of other medical services, such
as HCV testing.
Using data from two recent rounds of the NDTASS,
















































Fig. 1 Estimates of the Association between State-level HIV Pre-Test Counseling Policies and Availability of Hepatitis C Testing Services in Opioid
Treatment Programs, by Type of Drug Treatment Program. Notes: the figures presented here are predicted probabilities obtained from logistic
regressions with state fixed-effects. The analytical sample in these models includes all OTPs in states where the HIV-relation legislation changed
between 2005 and 2011. Error bars represent 95% confidence intervals. An interaction term between type of treatment program and adoption
statelevel HIV-related legislation was significant at p<0.05 level. This model includes controls for other characteristics of OTPs listed in table 2.
Standard errors are adjusted for clustering of observations within state
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Ratio (95 % CI)b
Adjusted Odds
Ratio (95 % CI)b
State-level legislation enables eliminating HIV pretest counseling requirement <0.01
No 42 (31.3) 92 (68.7) 1 1
Yes 106 (59.2) 73 (40.8) 0.31 (0.20, 0.50) 1.65 (0.32, 8.46)
Prevalence of injection drug users 0.06
< 25 % 57 (57.0) 43 (43.0) 1 1
25-74 % 57 (41.6) 80 (58.4) 1.86 (1.10, 3.14) 2.68 (1.11, 6.47)
≥ 75 % 33 (46.5) 38 (53.5) 1.53 (0.83, 2.82) 0.69 (0.24, 2.01)
African-American patients 0.49
< 10 % 73 (49.3) 75 (50.7) 1 1
≥ 10 % 75 (45.4) 90 (54.6) 1.17 (0.75, 1.82) 0.97 (0.41, 2.30)
Hispanic patients 0.70
< 10 % 75 (48.4) 80 (51.6) 1 1
≥ 10 % 73 (46.2) 85 (53.8) 1.09 (0.70, 1.70) 1.26 (0.50, 3.16)
Revenue from federal government 0.01
None 114 (51.8) 106 (48.2) 1 1
≥ 1 % 33 (36.6) 59 (63.4) 1.87 (1.13, 3.07) 2.47 (1.04, 5.88)
Revenue from private insurance 0.11
None 80 (43.5) 104 (56.5) 1 1
≥ 1 % 48 (52.7) 61 (47.3) 0.69 (0.44, 1.08) 1.33 (0.59, 2.98)
Human resources
Log Staff-to-patient ratio, mean (SD) -3.40 (0.78) -3.24 (0.66) 0.05 1.36 (0.99, 1.88) 1.80 (1.10, 2.93)
CARF accreditation 0.21
No 76 (51.0) 73 (49.0) 1 1
Yes 72 (43.9) 97 (56.1) 1.33 (0.85, 2.08) 1.37 (0.60, 3.12)
Ownership <0.01
Private not-for-profit 77 (52.0) 71 (48.0) 1 1
Private for profit 61 (50.4) 60 (49.6) 1.07 (0.66, 1.73) 1.52 (0.66, 3.46)
Public 10 (22.7) 34 (77.3) 3.69 (1.70, 8.02) 3.36 (0.95, 11.9)
Hospital affiliation <0.01
No 134 (51.3) 127 (48.6) 1 1
Yes 14 (26.9) 38 (73.1) 2.86 (1.48, 5.54) 6.22 (2.04, 18.9)
Methods of treatment <0.01
Methadone only 69 (40.1) 103 (59.9) 1 1
Buprenorphine only 55 (75.3) 18 (24.7) 0.22 (0.12, 0.41) 0.17 (0.06, 0.49)
Methadone + Buprenorphine 24 (35.3) 44 (64.7) 1.23 (0.68, 2.20) 2.95 (1.19, 7.31)
Time <0.01
2005 38 (27.7) 99 (72.3) 1 1
2011 110 (62.5) 66 (37.5) 0.23 (0.14, 0.37) 0.10 (0.02, 0.45)
N 148 (47.3) 165 (52.7) 313 282c
Notes: apercentages in parentheses are column percentages; badjusted odds ratios are obtained from a logistic regression in which all variables in the table are included as
independent variables. Standard errors are adjusted for clustering of observations by state. cOnly states in which laws changed between 2005 & 2011 are included in model
with state-level fixed effects. p-value derived from a Wald test showed that at least one of the state dummies included in the model is significant at p< 0.05
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that offered only buprenorphine treatment to their pa-
tients for substance abuse treatment, legislative changes
that permitted dropping the pretest counseling require-
ment for HIV testing were associated with significantly
higher availability of HCV testing. On the other hand, in
OTPs that offered methadone to their patients for sub-
stance abuse treatment, there were no differences in
HCV testing availability between states with and without
a legal requirement for HIV-related pretest counseling.
There are several reasons why the elimination of pretest
counseling for HIV testing may affect HCV testing in OTPs
that offer only buprenorphine. First, this may be related to
the type of patient population served by buprenorphine-
only programs [34, 38, 39]. Programs that adopt buprenor-
phine are more reliant on revenue from private insurance
and patient self-pay [40]. They are also less likely to treat
persons who inject drugs as a method of substance use
[28, 41] and they often treat patients that use other opiates
instead of heroin [41]. Buprenorphine-only programs may
therefore be less likely to consider their patient population
as at-risk for HIV or HCV and to invest in the resources re-
quired to provide testing services. The elimination of pre-
test counseling may have reduced the investment required
for offering HIV testing (i.e., time required to provide pre-
test counseling and complete testing) and may have indir-
ectly influenced the offer of other preventive services,
including HCV testing.
Second, we suggest that the removal of the requirement
to provide pretest counseling for HIV may have reduced
concerns of stigma among the patient population and pro-
viders of buprenorphine-only programs. Patients of these
programs may indeed be more likely to associate pretest
counseling messages with stigmatized behaviors such as
injecting drug use, thus reducing their demand for testing
services [42, 43]. Streamlining the HIV testing process
through the elimination of the pretest counseling re-
quirement may therefore increase the acceptability of
testing for HIV and HCV among patients and providers in
buprenorphine-only programs. It may help these programs
adopt HCV testing as standard medical practice [44].
Finally, there may be aspects of the operating environ-
ment of buprenorphine-only programs that make them
more responsive to legislative changes than methadone pro-
grams. Whereas methadone maintenance programs must
be certified by SAMHSA, licensed at the state level and pro-
vide directly observed therapy (in some case patients may
be eligible for take-home methadone), buprenorphine-only
programs solely need to have on staff a health care provider
who has obtained DEA approval to prescribe controlled
substances. The less structured operational requirements of
buprenorphine-only programs may thus make it easier for
these programs to invest resources in HCV testing follow-
ing the adoption of legislative changes. This may account



















































Fig. 2 Estimates of the Association between State-level HIV Pre-Test Counseling Policies and Availability of Hepatitis C Testing Services On-site in
Opioid Treatment Programs, by Type of Drug Treatment Program. Notes: the figures presented here refer to OTPs, which offer at least some kind
of HCV testing services (i.e., on-site or offsite). The figures reported are predicted probabilities obtained from logistic regressions with state fixed-effects.
The analytical sample in these models includes all OTPs in states where the HIV-relation legislation changed between 2005 and 2011. Error bars represent
95 % confidence intervals. In this model, there was no significant interaction between type of treatment program and adoption of legislation consistent
with CDC guidelines. Standard errors are adjusted for clustering of observations within state
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removal of the HIV pre-test counseling requirement and
HCV testing practices across different types of OTPs.
Our results also indicated that HIV-related legislation
did not translate into an increase in the offer of on-site
testing among OTPs that offered HCV testing. This is
likely sub-optimal since on-site services are significantly
more effective at improving uptake of testing among pa-
tients of drug treatment programs than off-site services [6,
45]. Changes in HIV-related legislation may not have lead
to the adoption of on-site HCV testing for reasons related
to the standard HCV testing algorithm. Indeed, until re-
cently HCV anti-body testing was based on collection of
blood specimen obtained by venipuncture [46, 47]. Pro-
grams that do not have the required human or financial
resources to conduct on-site testing (e.g., buprenorphine-
only programs) may instead offer testing services through
referral sources. However, the introduction and adoption
of rapid HCV testing may improve the availability of on-
site HCV testing. Rapid HIV testing is often preferred to
conventional testing, given the ease of testing and imme-
diacy of results [48, 49]. It is also associated with increased
uptake of testing [50–52]. Thus, an increase in on-site
HCV testing may be facilitated by the adoption of rapid
HCV testing [53]. Interventions that effectively integrate
rapid HIV and rapid HCV testing and treatment services
are needed [15, 54].
Several other factors may further improve the adoption
of HCV testing in OTPs. This includes the 2012 CDC rec-
ommendation to expand HCV testing to include persons
born between 1945 and 1965 [55], or the advent of highly
effective and efficient antiretroviral treatments for HCV
[56]. Expansion of testing for HCV is important because
similar to HIV, diagnosis and awareness of one’s infection
status sets into motion a continuum of care, which in the
case of HCV can lead to a cure [57].
Our results improve on previous evaluations of the ef-
fects of HIV-related legislation [6, 9, 10, 58, 59] by inves-
tigating the “spillover effects” of HIV-related legislation
on non-HIV services. Such effects are important to take
into account when evaluating the cost-effectiveness of
legislative changes. Indeed, improvements in the avail-
ability of HCV testing services following modifications
of the pretest counseling requirement for HIV testing
could benefit patients in multiple ways. They may lead
to an earlier detection, and thus better clinical manage-
ment, of HIV/HCV co-infection. They may lead to re-
ductions in incidence of HIV and/or HCV if patients
learning their HIV and/or HCV serostatus modify their
risk behaviors and adopt protective measures. The spill-
over effects of HIV-related legislations may also extend
beyond the availability of HCV testing services. For ex-
ample, dropping the requirement for HIV pretest counsel-
ing may allow health workers in SUD treatment programs
to spend more time on substance use counseling. This
may in turn lead to increasing SUD treatment completion
rates and/or improving patient outcomes (e.g., sobriety at
treatment completion, fewer relapses). It may also im-
prove the availability of a broad range of other medical
services such as vaccination against hepatitis B, STI testing
and similar diseases. The impact of changes in HIV-
related legislation on epidemiological trends and estimates
of healthy life expectancy may thus be larger than previ-
ously thought [60, 61].
While HIV testing policies may have a spillover effect
on HCV testing practices, increasing the availability of
HCV testing will require a multi-pronged approach.
Consent and counseling guidelines focused on HCV
may inform state policies on the issue, but state adop-
tion of existing guidelines and their direct effects on
HCV testing practices has not been examined [16, 55].
Future studies should therefore systematically assess var-
iations in HCV testing polices across states and their im-
pact on OTPs’ testing practices. Additionally, adequate
resources must be devoted to the prevention, control
and surveillance of HCV [62]. Unfortunately, the U.S.
Department of Health and Human Services report on
“Action Plan to Prevent, Care and Treat Viral Hepatitis”,
which was released in 2011 and updated in 2014, did not
include a provision to increase funding for viral hepatitis
[63]. The Affordable Care Act (ACA) expansion of cover-
age for treatment of SUDs and hepatitis prevention, diag-
nosis, care, and treatment however present a promising
pathway to improving access and patient outcomes [64].
Additionally, as newer more effective medications for
HCV become available, it would be important to examine
whether and how lessons learned about the HIV care con-
tinuum could be applied to the HCV care continuum to
improve case identification and treatment outcomes [65].
This study has several limitations. First, the NDATSS
had limited questions on patients of OTPs. We therefore
could not measure the relationship between HIV pretest
counseling policies and uptake of HCV testing services
among patients. Second, we also could not determine
the influence of length of time since elimination of pre-
test counseling on HCV testing practices. Specifically,
we do not know how long after a State changed its legis-
lation, the OTPs in that State changed their HIV testing
practices, including removal of the pre-test counseling
requirement. This is important because an OTP with
more experience implementing the guidelines, e.g., a
program operating under elimination of pretest counsel-
ing for a year, may have better knowledge about the in-
fluence of the policy on operating procedures, and may
therefore be more likely to offer HCV testing services.
On the other hand, a program that has newly eliminated
pretest counseling may be less likely to offer HCV test-
ing services. Third, we performed separate analyses to
assess the associations between State legislation on HIV
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testing and a) HCV testing (either on-site or off-site), as
well as b) on-site HCV testing in OTPs. This was necessary
because of limited sample size. Future studies should rely
on larger samples, and should employ other methodological
approaches (multinomial regression) to further extend our
findings. Lastly, the NDATSS data do not permit assessing
whether the relation between HIV testing policies and
HCV testing practices is causal. Even though we included
state-level fixed-effects in our models, these only control
for time-invariant characteristics of states that may con-
found the relationship between legislative changes and
HCV testing. They do not account for a) characteristics of
states that changed between 2005 and 2011, and b) unob-
served characteristics of OTPs. Addressing this issue re-
quires panel data on OTPs and their practices, i.e., a
sample of OTPs that are repeatedly surveyed over time.
Unfortunately, only a small number of OTPs in the
NDATSS were interviewed both in 2005 and 2011, thus
precluding such robust causal analyses. In addition, our
data does not permit determining whether OTPs adopted
HCV testing before or after the State in which they are lo-
cated changed its HIV-related legislation. This is so because
we only know whether surveyed OTPs offered HCV testing
in 2005 or 2011. We do not know when exactly they first
adopted HCV testing. As a result, we can only identify as-
sociations between HIV-related state laws and HCV testing
practices in OTPs.
Conclusions
Our results highlight some of the implications of
HIV policies for the availability of non-HIV services.
Buprenorphine-only programs were more likely to offer
HCV testing services in states that mandated the elimin-
ation of HIV pretest counseling, but this was not the case
for methadone programs. Changes in legislation related to
HIV pretest counseling also were not associated with the
availability of on-site HCV testing. Our findings underscore
several areas for future research. There is a need for
a better understanding of the mechanisms (i.e., man-
agerial decision-making) or pathways (i.e., translation
of polices in service delivery settings) through which HIV
pretest counseling policies influence non-HIV services.
Additionally, studies should investigate the impact of HIV
testing policies on HCV testing services, considering state
guidelines for HCV testing. Lastly, the longer-term effect
of eliminating HIV pretest counseling on clients and their
use of HIV-related services, and whether programs intro-
ducing HCV testing after the elimination of HIV pretest
counseling provide pre-test counseling for HCV testing
should be examined in future studies. These analyses will
provide a more in-depth understanding of the role of pol-
icy interventions in shaping HCV testing practices, pro-
mote the effective integration of HIV and HCV services,
and increase the availability of HCV testing in substance
abuse treatment programs and other health care settings.
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